Dilated Cardiomyopathy Therapeutics Market: Growing Incidence of Cardiac Diseases to Catapult Asia Pacific to Lead Position
Transparency Market Research in a recent publication says competition in the global dilated cardiomyopathy therapeutics market is expected to grow as prominent companies strive to develop effective drugs for the treatment of dilated cardiomyopathy. For example, in February 2017, Myokardia Inc., a biopharmaceutical company, announced first time administer of MYK-491 to a batch of healthy subjects. MYK-491 is a treatment for dilated cardiomyopathy which is in Phase 1.
View full press release